Literature DB >> 20965899

Incidental fleurodeoxyglucose uptake in the prostate.

W L Wong1, R N Moule, T Nunan.   

Abstract

This commentary confirms the rarity of prostatic cancer associated with incidental prostatic fleurodeoxyglucose (FDG) uptake. The study adds to the literature by showing that even if a prostate lesion is FDG avid it is unlikely to be due to cancer. The commentary considers the management of incidental prostate FDG uptake on the basis of the available evidence.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20965899      PMCID： PMC3473722          DOI： 10.1259/bjr/28173921

Source DB:  PubMed          Journal:  Br J Radiol        ISSN： 0007-1285            Impact factor:   3.039


  16 in total

1.  Screening for cancer with high technology imaging tests.

Authors:  Bruce J Hillman
Journal:  J Clin Oncol       Date:  2009-03-02       Impact factor: 44.544

Review 2.  PET-CT for treatment planning in prostate cancer.

Authors:  M Picchio; C Crivellaro; G Giovacchini; L Gianolli; C Messa
Journal:  Q J Nucl Med Mol Imaging       Date:  2009-04       Impact factor: 2.346

3.  How do oncologists deal with incidental abnormalities on whole-body fluorine-18 fluorodeoxyglucose PET/CT?

Authors:  Guohui Wang; Eddie W F Lau; Ramdave Shakher; Danny Rischin; Robert E Ware; Emily Hong; David S Binns; Annette Hogg; Elizabeth Drummond; Rodney J Hicks
Journal:  Cancer       Date:  2007-01-01       Impact factor: 6.860

4.  Diffuse FDG uptake in acute prostatitis.

Authors:  Pan-Fu Kao; Yu-Hsiang Chou; Chieh-Wen Lai
Journal:  Clin Nucl Med       Date:  2008-04       Impact factor: 7.794

5.  Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context.

Authors:  Gerrit Draisma; Ruth Etzioni; Alex Tsodikov; Angela Mariotto; Elisabeth Wever; Roman Gulati; Eric Feuer; Harry de Koning
Journal:  J Natl Cancer Inst       Date:  2009-03-10       Impact factor: 13.506

6.  The value of 18F-fluorodeoxyglucose positron emission tomography with the additional help of tumor markers in cancer screening.

Authors:  Y Y Shen; C T Su; G J S Chen; Y K Chen; A C F Liao; F S Tsai
Journal:  Neoplasma       Date:  2003       Impact factor: 2.575

Review 7.  The roles of PET and PET/CT in the diagnosis and management of prostate cancer.

Authors:  Nobukazu Takahashi; Tomio Inoue; Jin Lee; Takako Yamaguchi; Kazuya Shizukuishi
Journal:  Oncology       Date:  2008-01-07       Impact factor: 2.935

8.  Cancer screening of healthy volunteers using whole-body 18F-FDG-PET scans: The Nishidai clinic study.

Authors:  Shinsuke Kojima; Bin Zhou; Satoshi Teramukai; Akiko Hara; Noboru Kosaka; Yoshitomo Matsuo; Hitoshi Suzuki; Soichiro Torigoe; Takayuki Suzuki; Kimiichi Uno; Masanori Fukushima
Journal:  Eur J Cancer       Date:  2007-07-05       Impact factor: 9.162

9.  Cancer screening with FDG-PET.

Authors:  M Ide
Journal:  Q J Nucl Med Mol Imaging       Date:  2006-03       Impact factor: 2.346

10.  Prospective evaluation of whole-body cancer screening with multiple modalities including [18F]fluorodeoxyglucose positron emission tomography in a healthy population: a preliminary report.

Authors:  Sadahiko Nishizawa; Shinsuke Kojima; Satoshi Teramukai; Masayuki Inubushi; Hironobu Kodama; Yoshiki Maeda; Hiroyuki Okada; Bin Zhou; Yoji Nagai; Masanori Fukushima
Journal:  J Clin Oncol       Date:  2009-03-02       Impact factor: 44.544
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.